Loading insider details...
Beta
Latest Form 4 (Jun 23, 2026): Exercise/Conversion of 47,700 ALLO shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 23, 2026 | Allogene Therapeutics, Inc. (ALLO) | Exercise/Conversion | 47,700 | n/a |
| Dec 22, 2025 | Allogene Therapeutics, Inc. (ALLO) | Exercise/Conversion | 47,700 | n/a |
| Jun 24, 2025 | Allogene Therapeutics, Inc. (ALLO) | Grant/Award | 94,500 | n/a |
| Jun 26, 2024 | Kronos Bio, Inc. (KRON) | Grant/Award | 34,000 | n/a |
| Jun 7, 2024 | Allogene Therapeutics, Inc. (ALLO) | Grant/Award | 191,082 | n/a |
| Jun 15, 2023 | Allogene Therapeutics, Inc. (ALLO) | Grant/Award | 116,120 | n/a |
| Jun 17, 2022 | Allogene Therapeutics, Inc. (ALLO) | Grant/Award | 44,178 | n/a |
| Mar 9, 2022 | Allogene Therapeutics, Inc. (ALLO) | Other (see footnotes) | 412,618 | n/a |
| Jan 14, 2022 | Allogene Therapeutics, Inc. (ALLO) | Purchase | 15,000 | $189.0K |
| Jun 11, 2021 | Allogene Therapeutics, Inc. (ALLO) | Grant/Award | 16,498 | n/a |